Parsons Austin J, Franco-Palacios Domingo, Kelly Bryan, Grafton Gillian, McIntosh Javardo, Coleman David, Abdul Hameed Asif M, Sayf Alaa Abu
Department of Internal Medicine Henry Ford Hospital Detroit Michigan USA.
Division of Pulmonary Medicine, Henry Ford Hospital Detroit Michigan USA.
Pulm Circ. 2025 Jan 1;15(1):e70034. doi: 10.1002/pul2.70034. eCollection 2025 Jan.
Common variable immunodeficiency (CVID) is a type of primary immunodeficiency that presents as a heterogenous disorder characterized by hypogammaglobinemia, poor response to vaccines, recurrent sinopulmonary infections, and can have noninfectious systemic manifestations. We performed a single-center, retrospective, observational study of five patients with noninfectious complications of CVID. All patients had CVID as defined by the European Society of Immunodeficiencies criteria and had received intravenous immunoglobulin therapy. There were multiple pulmonary manifestations of CVID including frequent pneumonias, bronchiectasis, granulomatous lung disease, and pulmonary hypertension. All our patients were treated with pulmonary vasodilators for severe precapillary pulmonary hypertension along with individualized immunosuppression regimen for interstitial lung disease. Despite treatment for interstitial lung disease and PH, their conditions worsened over 2-3 years with all patients progressing toward organ transplant evaluation. Idiopathic thrombocytopenia and non-cirrhotic portal hypertension were common, with three patients probably suffering from nodular regenerative hyperplasia. Noninfectious complications of CVID can affect different organs and progress despite advanced therapies. Single or multiorgan transplantation is a treatment option for patients with end-stage organ involvement refractory to medical therapy.
普通可变免疫缺陷(CVID)是一种原发性免疫缺陷病,表现为一种异质性疾病,其特征为低丙种球蛋白血症、对疫苗反应不佳、反复发生鼻窦肺部感染,且可能有非感染性全身表现。我们对5例患有CVID非感染性并发症的患者进行了一项单中心、回顾性观察研究。所有患者均符合欧洲免疫缺陷学会标准所定义的CVID,并接受了静脉注射免疫球蛋白治疗。CVID有多种肺部表现,包括频繁肺炎、支气管扩张、肉芽肿性肺病和肺动脉高压。我们所有患者均接受了用于治疗重度毛细血管前肺动脉高压的肺血管扩张剂,以及针对间质性肺病的个体化免疫抑制方案。尽管对间质性肺病和肺动脉高压进行了治疗,但他们的病情在2至3年内仍恶化,所有患者都进展到需要进行器官移植评估。特发性血小板减少症和非肝硬化性门静脉高压很常见,有3例患者可能患有结节性再生性增生。尽管有先进的治疗方法,CVID的非感染性并发症仍可影响不同器官并进展。对于药物治疗难以控制的终末期器官受累患者,单器官或多器官移植是一种治疗选择。